1 The EIC Accelerator Project

The EIC Accelerator program is a pivotal component of the European Innovation Council, aimed at fostering innovation and entrepreneurship across Europe. This program specifically targets startups and small and medium-sized enterprises (SMEs) with high-impact innovations in various sectors, including DeepTech. The EIC Accelerator provides a unique combination of grant and equity funding to support these companies in their growth and development.

Funding Structure

The EIC Accelerator offers two main forms of funding: grants and equity investments.

Purpose and Impact

The EIC Accelerator plays a crucial role in the European DeepTech and startup ecosystem by filling funding gaps that often exist in early-stage innovation. The program is designed not only to provide financial support but also to enhance the visibility of promising startups, thereby increasing their chances of securing additional funding from private sector investors. By supporting high-risk, high-reward innovations, the EIC Accelerator contributes to the overall competitiveness and technological advancement of the European market.

Scaling and Funding

The EIC Accelerator actively works to help companies scale their operations by providing tailored support that extends beyond mere funding. This includes access to mentorship, networking opportunities, and strategic partnerships. By helping companies navigate the complex landscape of innovation and investment, the EIC Accelerator enhances their ability to attract private sector funding, which is often crucial for sustainable growth.

Case Study: Camino Science sp. z o.o. and Project in silico bio-evolutio

Camino Science sp. z o.o., a Polish startup, emerged as a notable winner of the EIC Accelerator with its project titled in silico bio-evolutio. The project focuses on a novel artificial intelligence paradigm for molecular biology, representing a significant advancement in computational biology.

Technology Overview

The in silico bio-evolutio project aims to leverage artificial intelligence to revolutionize the way molecular biology is approached, particularly in the realms of drug discovery, genetic engineering, and synthetic biology. The technology integrates advanced machine learning algorithms with biological data to facilitate the prediction and optimization of molecular interactions.

In molecular biology, traditional methods of experimentation can be time-consuming and costly. By employing an AI-driven approach, Camino Science seeks to streamline the process of identifying viable molecular candidates for various applications, effectively reducing the time and resources needed for research and development.

The background of this technology lies in the increasing complexity of biological systems and the need for more efficient methodologies to analyze and interpret vast amounts of biological data. Machine learning models can analyze patterns and correlations that may not be immediately apparent to researchers, enabling faster and more accurate predictions regarding molecular behavior.

Project Goals and Impact

The primary goals of the in silico bio-evolutio project include enhancing the efficiency of molecular biology research, reducing the costs associated with drug discovery, and ultimately contributing to the development of innovative therapeutic solutions. By improving the predictive capabilities in molecular interactions, the project has the potential to accelerate the pace of scientific discovery and enable breakthroughs in healthcare and biotechnology.

In summary, the EIC Accelerator program, through its innovative funding structure and supportive ecosystem, plays a fundamental role in nurturing the next generation of European startups like Camino Science. By providing critical financial and strategic resources, the EIC Accelerator not only promotes technological advancement but also strengthens the overall landscape of innovation across Europe.

2 The Funding Rounds

# Camino Science: EIC Accelerator Funding Recipient

Camino Science, a Polish company, secured funding through the European Innovation Council (EIC) Accelerator program following the March 23, 2022 cut-off date. This highly competitive funding program supports innovative startups and SMEs across Europe with both grants and equity investments.

EIC Accelerator Funding Details

Camino Science was among the companies selected in the March 2022 EIC Accelerator call, which distributed a total of €382 million to 74 innovative companies. The funding was awarded under the HORIZON-EIC-2022-ACCELERATOR-01 call, specifically under the topic HORIZON-EIC-2022-ACCELERATOROPEN-01, which focuses on disruptive innovations across any technological field.

The company's project, "In Silico Bio-Evolutio," received financial support through the EIC Accelerator Grant. While the exact funding amount specifically for Camino Science is not detailed in the available information, the EIC Accelerator typically provides substantial financial support through:

• Grant funding of up to €2.5 million
• Equity investments through the EIC Fund ranging from €0.5 to €15 million

Funding Structure

The EIC Accelerator offers three types of funding: - Blended finance (combining grants with equity investments)

• Grant-only funding
• Equity-only investments

In the March 2022 call, companies like Camino Science benefited from the EIC's comprehensive funding approach, designed to support breakthrough innovations through both direct grants and equity investments that can help attract additional private investors.

Application Process

Camino Science successfully navigated the EIC Accelerator's rigorous application process, which consists of:

The company submitted its Step 2 proposal for the March 23, 2022 cut-off and subsequently succeeded in the Step 3 interview phase, securing the funding.

Post-Funding Support

Beyond financial support, EIC Accelerator recipients like Camino Science also receive:

• Business coaching and mentoring
• Access to EIC networks and events
• Additional business acceleration services

Context of EIC Accelerator Program

The EIC Accelerator is one of Europe's most competitive funding programs, supporting game-changing innovations. The program focuses on supporting deep tech companies with high growth potential that might be too risky for private investors alone. For the March 2022 call, Germany, France, and Finland were the top three countries receiving funding, with Poland also being represented through companies like Camino Science.

The funding aims to bridge the critical financing gap between late-stage innovation and market entry, helping companies scale up their technologies and reach commercial success.

Sources: - https://camino.science/?page_id=22225

• https://eic.ec.europa.eu/system/files/2022-06/EIC%20Accelerator-March%2023%20Cut%20Off%20v2.pdf
• https://www.strata.team/eic-accelerator-winners-march-2022/
• https://investny.org/companies/camino_science

3 The Press Releases

Camino Science Sp. z o.o. Overview

Camino Science Sp. z o.o. is a biotech company based in Poland, specifically operating in Bialystok. The company was established on March 25, 2020, and operates in the sector of Computer Systems Design and Related Services. However, it describes itself as a biotech company focused on using artificial intelligence to accelerate in vitro experiments through in silico predictions and explanations.

EIC Accelerator Funding

Camino Science Sp. z o.o. received funding under the European Innovation Council (EIC) Accelerator program in March 2022. Their project, titled "in silico bio-evolutio," aims to introduce a novel AI paradigm for molecular biology. This funding supports innovative technologies and represents a significant milestone for the company in advancing its mission to enhance biotech progress.

Technology and Mission

The company's primary mission is to improve human life by accelerating biotech progress. They achieve this by leveraging AI to predict and explain biological processes, which helps in speeding up in vitro experiments. This approach aligns with the broader goal of making scientific thought more efficient and effective.

Recent Developments

As of the latest available information, there are no detailed press releases or updates on partnerships, team updates, patents, or technology advancements directly related to Camino Science on their website or social media channels. However, it is noted that Camino Science reported a net sales revenue increase of 22.06% in 2023, although their total assets experienced a negative growth of 59.03%.

Conclusion

Camino Science Sp. z o.o. is a Polish biotech company that has made significant strides in leveraging AI for molecular biology through its "in silico bio-evolutio" project. The EIC Accelerator funding in March 2022 marked an important step in their development, supporting their mission to accelerate biotech advancements.

Sources: - EIC Accelerator winners March 2022

• Camino Science Sp. z o.o. Company Profile
• Camino Science Sp. z o.o. — Consulting Organization from Poland

4 The Technology Advancements

Camino Science sp. z o.o. from Poland

Since receiving the EIC Accelerator funding on March 23, 2022, Camino Science has been focused on leveraging advanced AI algorithms to predict molecular interactions through its groundbreaking platform. The company's key offerings include predictive analytics, drug discovery solutions, agricultural optimization, environmental impact assessment, and custom AI model development. However, there is limited publicly available information specifically detailing advancements or new developments made by Camino Science since the funding.

Current Capabilities

Camino Science's platform is designed to accelerate bioTech progress by predicting organism interactions, which provides valuable insights for research and applications across various industries. Their solutions are aimed at optimizing drug discovery processes, agricultural yield, and environmental sustainability by understanding complex biological systems.

Advancements and New Features

The search results do not provide specific information on new features or advancements introduced by Camino Science since the funding. However, the company's ongoing mission involves enhancing its AI-driven capabilities to support clients in diverse sectors.

Market Demonstration

There is no detailed information available on whether Camino Science has demonstrated its technology in the market through customer trials, pilots, or clinical trials since receiving the EIC funding.

Patents, Scientific Studies, and Publications

No recent patents, scientific studies, or whitepapers attributed to Camino Science have been identified in the available data. It is possible that such developments are ongoing but not publicly disclosed.

Conclusion

Camino Science continues to focus on developing AI-driven solutions for biological predictions, but specific details about advancements or market deployment since the EIC Accelerator funding are not readily available in public records.

Sources

• Camino Science – Camino In silico platform
• There are no specific sources detailing Camino Science's advancements since receiving the EIC Accelerator funding.

5 The Partnerships and Customers

Camino Science sp. z o.o.: Partnerships and Strategic Positioning Post-EIC Accelerator Funding

Based on available information, specific customer names and direct partnership announcements for Camino Science sp. z o.o. are not explicitly disclosed in public records. However, the company’s activities since its EIC Accelerator funding (awarded non-dilutive European Commission grants) highlight its focus on AI-driven biotechnology solutions for drug discovery, agricultural optimization, and environmental impact assessments. Below is a synthesis of its operational positioning:

Key Offerings Driving Collaborations

• Predictive AI Platform: Accelerates drug discovery by modeling molecular interactions, reducing R&D timelines.
• Custom AI Models: Tailored solutions for clients in pharmaceuticals, agriculture, and sustainability sectors.
• Environmental Impact Tools: Focus on ecosystem preservation through organism-environment interaction modeling.

Market Positioning Through Relationships

As a Poland-based biotechnology innovator, Camino Science likely collaborates with pharmaceutical companies, agricultural enterprises, and policy organizations requiring predictive analytics. Its EIC funding underscores alignment with EU innovation priorities, potentially facilitating partnerships with academic institutions or cross-border biotech consortia. While no named partners are listed publicly, their mission to "speed up bioTech progress" suggests engagements with entities seeking rapid in silico experimentation workflows.

Technology Advancements & Scaling

The company’s proprietary AI models aim to replace resource-intensive in vitro experiments with computational predictions. By focusing on scalable SaaS-like platforms for biological data analysis, Camino could attract clients needing cost-effective R&D acceleration. Their expertise in enzyme/protein optimization (similar to Bota Bio’s synthetic biology framework described in documentation) further positions them as a partner for industrial biomanufacturing ventures, though direct affiliations remain unspecified.

---

Sources

• Camino Science – In silico platform
• DevelopmentAid profile
• Camino overview documentation

6 The Hiring and Company Growth

Camino Science sp. z o.o. Overview

Camino Science sp. z o.o. is a Polish company established on March 25, 2020, operating primarily in the computer systems design and related services sector. The company is based in Bialystok, Poland, and has been involved in biotech, focusing on enhancing human life through in vitro experiments accelerated by in silico predictions and explanations.

Hiring and Team Growth

As of the latest available information, there is no specific data on the current headcount or team size of Camino Science. Additionally, there are no details on whether they are currently hiring or have recently filled key positions. The company's growth trajectory is marked by a significant increase in net sales revenue, with a reported 22.06% rise in 2023.

Funding and Growth

Camino Science was an EIC Accelerator winner in March 2022, receiving funding that likely contributed to its growth. This funding typically supports innovative projects and companies, enabling them to scale and expand their operations. However, specific details on how this funding has impacted their team size or management are not available.

Future Implications

The EIC Accelerator funding is crucial for companies like Camino Science, as it provides the necessary resources to accelerate their biotech advancements. New team members would likely be involved in expanding the company's capabilities in in silico predictions and in vitro experiments, contributing to its mission of enhancing human life through bioTech progress. While there are no specific details on recent management changes, the growth and funding suggest a focus on strategic team expansion to support their mission.

Conclusion

Camino Science sp. z o.o. has demonstrated significant financial growth and is positioned in a strategic sector for innovation. However, detailed information on current hiring practices, team size, or specific management changes is not readily available. The company's focus on biotech innovation and its recent funding suggest a promising future, with potential for significant scaling and growth.

Sources

• EMIS: Camino Science Sp. z o.o. Company Profile
• Development Aid: Camino Science Sp. z o.o.
• Poland Dealroom: Camino Science

7 The Media Features and Publications

Overview of Camino Science sp. z o.o.

Camino Science sp. z o.o., a Polish biotech company, was a recipient of the EIC Accelerator funding in March 2022. The company focuses on accelerating biotech progress through in silico predictions and explanations, aiming to enhance molecular biology research and drug discovery.

Media Features and Publications

Currently, there are no specific media features or publications directly mentioning Camino Science sp. z o.o. However, the company itself highlights its mission and goals on its official website.

Podcasts and Interviews

There is no available information about podcasts or interviews featuring the team of Camino Science sp. z o.o.

Conference and Fair Visits

Details about Camino Science sp. z o.o.'s participation in conferences, fairs, or presentations are not readily available. However, the company's involvement in scientific events may be connected to its role as a bioinnovation partner in the biotech and pharma industries.

Involvement in Events

Camino Science sp. z o.o. is likely to be involved in events related to biotechnology, drug discovery, and molecular biology, given its focus on these areas. However, specific details about such events are not available.

Conclusion

Camino Science sp. z o.o. is a biotech company leveraging AI for drug discovery and molecular interactions. Despite limited public coverage and specific event participations, the company's role in advancing biotech through in silico methods is central to its mission.

Sources

• Camino Science – Camino In silico platform
• Company EDIOM SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
• Media – Camino Science